Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …

After being in the therapeutic wilderness for several decades, acute myeloid leukemia has
been recently thrust into the limelight with a series of drug approvals. Technical refinements …

In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …

Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …

Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …

CD33 is expressed by acute myeloid leukemia (AML) cells in> 80% of patients but not by
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …

Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal
antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially …

Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …

Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML).
Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for …